Printed from https://ideas.repec.org/s/spr/aphecp3.html
Content
February 2020, Volume 18, Issue 1
- 69-79 A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance
by David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins - 81-96 Why Do Informal Sector Workers Not Pay the Premium Regularly? Evidence from the National Health Insurance System in Indonesia
by Teguh Dartanto & Alin Halimatussadiah & Jahen Fachrul Rezki & Renny Nurhasana & Chairina Hanum Siregar & Hamdan Bintara & Usman & Wahyu Pramono & Nia Kurnia Sholihah & Edith Zheng Wen Yuan & Rooswanti Soeharno - 97-107 Estimating Attribute-Specific Willingness-to-Pay Values from a Health Care Contingent Valuation Study: A Best–Worst Choice Approach
by Ivan Sever & Miroslav Verbič & Eva Klaric Sever - 109-125 Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany
by Afschin Gandjour & Dennis A. Ostwald - 127-137 Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy
by Paula M. Murray & Yusuf A. Shalaby & Luciano Ieraci & Emmett Borg & Daphne Sniekers & Ali Vahit Esensoy & Jessica Arias - 139-140 Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”
by Muhammad Radzi Abu Hassan & Huan-Keat Chan - 141-141 Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
by Renée Else Michels & Maria Francesco & Koshu Mahajan & Gerald J. D. Hengstman & Krijn M. H. Schiffers & Sangeeta Budhia & Gerard Harty & Marieke Krol
December 2019, Volume 17, Issue 6
- 757-759 Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
by William V. Padula & R. Brett McQueen - 761-770 A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money
by Haitham W. Tuffaha & Joanne Aitken & Suzanne Chambers & Paul A. Scuffham - 771-780 A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
by Ash Bullement & Holly L. Cranmer & Gemma E. Shields - 781-801 A Review of the Development and Application of Generic Preference-Based Instruments with the Older Population
by Jenny Cleland & Claire Hutchinson & Jyoti Khadka & Rachel Milte & Julie Ratcliffe - 803-816 Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries
by Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen - 817-825 The Value Employees Place on Health Insurance Plans: A Discrete-Choice Experiment
by Stephen Poteet & Benjamin M. Craig - 827-839 Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting
by Gabriel Tremblay & Ben Rousseau & Miriam Marquis & Cyrielle Beaubois & Guy Sauvageau & Josée Hébert - 841-855 Using Adherence-Contingent Rebates on Chronic Disease Treatment Costs to Promote Medication Adherence: Results from a Randomized Controlled Trial
by Marcel Bilger & Tina T. Wong & Jia Yi Lee & Kaye L. Howard & Filipinas G. Bundoc & Ecosse L. Lamoureux & Eric A. Finkelstein - 857-873 Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
by Renée Else Michels & Maria Fransesco & Koshu Mahajan & Gerald J. D. Hengstman & Krijn M. H. Schiffers & Sangeeta Budhia & Gerard Harty & Marieke Krol - 875-882 In-Hospital Healthcare Utilization, Outcomes, and Costs in Pre-Hospital-Adjudicated Low-Risk Chest-Pain Patients
by Dominique N. Dongen & Jan Paul Ottervanger & Rudolf Tolsma & Marion Fokkert & Aize Sluis & Arnoud W. J. ‘t Hof & Erik Badings & Robbert J. Slingerland - 883-893 Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
by Rick A. Vreman & Joost W. Geenen & Anke M. Hövels & Wim G. Goettsch & Hubert G. M. Leufkens & Maiwenn J. Al - 895-902 What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population
by Kim Pauwels & Isabelle Huys & Minne Casteels & Yvonne Denier & Martina Vandebroek & Steven Simoens
October 2019, Volume 17, Issue 5
- 573-576 Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation
by Craig Mitton & Brayan V. Seixas & Stuart Peacock & Michael Burgess & Stirling Bryan - 577-590 Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers
by Simon Walker & Susan Griffin & Miqdad Asaria & Aki Tsuchiya & Mark Sculpher - 591-613 A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?
by Cheryl Jones & Suzanne M. M. Verstappen & Katherine Payne - 615-627 Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
by Richard F. Pollock & William J. Valentine & Steven P. Marso & Andreas Andersen & Jens Gundgaard & Nino Hallén & Deniz Tutkunkardas & Elizabeth A. Magnuson & John B. Buse - 629-640 The Economic Burden of Asthma in Greece: A Cross-Sectional Study
by Katerina Vellopoulou & Petros Bakakos & Stelios Loukides & Nikos Maniadakis & Georgia Kourlaba - 641-654 Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy
by Shui Ling Wong & Saliza Ibrahim & Norazlin Abdul Kadir & Salbiah Mohd Salleh - 655-667 Budget Impact Analysis of Molecular Lymph Node Staging Versus Conventional Histopathology Staging in Colorectal Carcinoma
by Sherley Diaz-Mercedes & Ivan Archilla & Jordi Camps & Antonio Lacy & Iñigo Gorostiaga & Dulce Momblan & Ainitze Ibarzabal & Joan Maurel & Nuria Chic & Josep Antoni Bombí & Francesc Balaguer & Antoni Castells & Iban Aldecoa & Josep Maria Borras & Miriam Cuatrecasas - 669-681 Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma
by Mbathio Dieng & Nikita Khanna & Nadine A. Kasparian & Daniel S. J. Costa & Phyllis N. Butow & Scott W. Menzies & Graham J. Mann & Anne E Cust & Rachael L. Morton - 683-705 Developing Attributes and Attribute-Levels for a Discrete-Choice Experiment: An Example for Interventions of Impulsive Violent Offenders
by Stella Nalukwago Settumba & Marian Shanahan & Tony Butler & Peter Schofield & Lise Lafferty & Paul Simpson & Georgina M. Chambers - 707-722 General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data
by Laurent M. Willems & Hajo M. Hamer & Susanne Knake & Felix Rosenow & Jens-Peter Reese & Adam Strzelczyk - 723-732 Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
by Ashleigh McGirr & Desiree Van Oorschot & Robyn Widenmaier & Michael Stokes & Michael L. Ganz & Hyosung Jung & Lijoy Varghese & Desmond Curran - 733-740 Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA
by Lotte Steuten & Vincent Garmo & Hemant Phatak & Sean D. Sullivan & Paul Nghiem & Scott D. Ramsey - 741-751 A Probe into the Wages and Salaries of Health Economics, Outcomes Research, and Market Access Professionals
by Manuel J. Carvajal & Patti Peeples & Ioana Popovici
August 2019, Volume 17, Issue 4
- 421-431 Why is There Discordance between the Reimbursement of High-Cost ‘Life-Extending’ Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia
by Sopany Saing & Naomi van der Linden & Christopher Hayward & Stephen Goodall - 433-441 Advanced Data Visualisation in Health Economics and Outcomes Research: Opportunities and Challenges
by Shelagh M. Szabo & Karissa M. Johnston & Andrew J. Lloyd - 443-452 A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine
by Patrick Fahr & James Buchanan & Sarah Wordsworth - 453-465 Mepilex Border Sacrum and Heel Dressings for the Prevention of Pressure Ulcers: A NICE Medical Technology Guidance
by C. Marshall & J. Shore & M. Arber & M. Cikalo & T. Oladapo & A. Peel & R. McCool & Michelle Jenks - 467-491 Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica
by James A. Hall & Kika Konstantinou & Martyn Lewis & Raymond Oppong & Reuben Ogollah & Sue Jowett - 493-511 Budget Impact Analysis of Cancer Screening: A Methodological Review
by Beate Jahn & Jovan Todorovic & Marvin Bundo & Gaby Sroczynski & Annette Conrads-Frank & Ursula Rochau & Gottfried Endel & Ingrid Wilbacher & Nikoletta Malbaski & Niki Popper & Jagpreet Chhatwal & Dan Greenberg & Josephine Mauskopf & Uwe Siebert - 513-521 The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
by Risha Gidwani-Marszowski & Douglas K. Owens & Jeanie Lo & Jeremy D. Goldhaber-Fiebert & Steven M. Asch & Paul G. Barnett - 523-532 Physical Activity and Healthcare Costs: Projections for Poland in the Context of an Ageing Population
by Małgorzata Kalbarczyk & Joanna Mackiewicz-Łyziak - 533-543 Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions
by Gregory Merlo & Katie Page & Pauline Zardo & Nicholas Graves - 545-554 Willingness to Pay for Cataract Surgeries Among Patients Visiting Eye Care Facilities in Dhaka, Bangladesh
by Muhammed Nazmul Islam & Thomas Engels & Shafayet Hossain & Malabika Sarker & Atonu Rabbani - 555-567 Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
by Carsten Hirt & Sergio Iannazzo & Silvia Chiroli & Lisa J. McGarry & Philipp Coutre & Leif Stenke & Torsten Dahlén & Jeffrey H. Lipton - 569-570 Comment on: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations”
by Salman Hussain & Ambrish Singh & Anwar Habib & Md Sarfaraj Hussain & Abul Kalam Najmi - 571-572 Authors’ Reply to Hussain et al.: “Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations”
by Martin Howell & Rachael Walker & Kirsten Howard
June 2019, Volume 17, Issue 3
- 265-271 Vaccination: Is There a Place for Penalties for Non-compliance?
by Tracey Chantler & Emilie Karafillakis & James Wilson - 273-284 The Value of Further Research: The Added Value of Individual-Participant Level Data
by Pedro Saramago & Manuel A. Espinoza & Alex J. Sutton & Andrea Manca & Karl Claxton - 285-294 Thopaz+ Portable Digital System for Managing Chest Drains: A NICE Medical Technology Guidance
by James Michael Evans & Alistair Ray & Megan Dale & Helen Morgan & Paul Dimmock & Grace Carolan-Rees - 295-313 An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values
by Clara Mukuria & Donna Rowen & Sue Harnan & Andrew Rawdin & Ruth Wong & Roberta Ara & John Brazier - 315-330 Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations
by Martin Howell & Rachael C. Walker & Kirsten Howard - 331-357 Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
by Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson - 359-370 The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort
by Padraig Dixon & George Davey Smith & William Hollingworth - 371-380 Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
by Lan Gao & Shu-Chuen Li - 381-389 A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case–Control Study
by Mehdi Touat & Marion Opatowski & Christian Brun-Buisson & Kristel Cosker & Didier Guillemot & Jerome Salomon & Philippe Tuppin & Gregoire de Lagasnerie & Laurence Watier - 391-397 Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes
by Anthony J. Hatswell & Joshua K. Porter - 399-410 A Transparent Universal Health Coverage Index with Decomposition by Socioeconomic Groups: Application in Asian and African Settings
by Jahangir A. M. Khan & Sayem Ahmed & Tao Chen & Ewan M. Tomeny & Louis W. Niessen - 411-417 Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
by Anna Kemp-Casey & Nicole Pratt & Emmae Ramsay & Elizabeth E. Roughead - 419-419 Correction to: Economic Evaluations of Childhood Hearing Loss Screening Programmes: A Systematic Review and Critique
by Rajan Sharma & Yuanyuan Gu & Teresa Y. C. Ching & Vivienne Marnane & Bonny Parkinson
April 2019, Volume 17, Issue 2
- 127-130 Re-design of Aged Care Environments is Key to Improved Care Quality and Cost Effective Reform of Aged and Health System Care
by Simon Eckermann & Lyn Phillipson & Richard Fleming - 131-141 ReCell® Spray-On Skin System for Treating Skin Loss, Scarring and Depigmentation after Burn Injury: A NICE Medical Technology Guidance
by Susan Caroline Peirce & Grace Carolan-Rees - 143-162 Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review
by Dominik J. Wettstein & Stefan Boes - 163-174 Family Spillover Effects in Pediatric Cost-Utility Analyses
by Tara A. Lavelle & Brittany N. D’Cruz & Babak Mohit & Wendy J. Ungar & Lisa A. Prosser & Kate Tsiplova & Montserrat Vera-Llonch & Pei-Jung Lin - 175-187 The Effect of Medical Insurance on Outpatient Visits by the Elderly: An Empirical Study with China Health and Retirement Longitudinal Study Data
by Chunjuan Qiu & Xianyi Wu - 189-211 Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance
by Francisca Crispi & Huseyin Naci & Eva Barkauskaite & Leeza Osipenko & Elias Mossialos - 213-230 Cost Effectiveness of New Diagnostic Tools for Cutaneous Leishmaniasis in Afghanistan
by Céline Aerts & Martijn Vink & Sayed Jalal Pashtoon & Sami Nahzat & Albert Picado & Israel Cruz & Elisa Sicuri - 231-242 Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System
by Leslie Wilson & Fatema Turkistani & Dang M. Tran & Wei Huang & Tracy Kuo Lin - 243-254 Real-World Cost Effectiveness of Mandatory Folic Acid Fortification of Bread-Making Flour in Australia
by Sopany Saing & Phil Haywood & Naomi van der Linden & Kathleen Manipis & Elena Meshcheriakova & Stephen Goodall - 255-256 Comment on: “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review”
by Carlos Vílchez-Román & Sol Sanguinetti & Edward Mezones-Holguín - 257-258 Comment on: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model”
by Paul Mintz - 259-261 Authors’ Reply to Mintz: “Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model”
by Laura T. Pizzi & Katherine M. Prioli & Jay H. Herman - 263-264 Correction to: Use of Expert Judgement Across NICE Guidance‑Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation
by Alison Peel & Michelle Jenks & Moni Choudhury & Rosemary Lovett & Juan Carlos Rejon‑Parrilla & Andrew Sims & Joyce Craig
February 2019, Volume 17, Issue 1
- 1-14 Ethically Acceptable Compensation for Living Donations of Organs, Tissues, and Cells: An Unexploited Potential?
by Trine Tornøe Platz & Nikolaj Siersbæk & Lars Peter Østerdal - 15-24 Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method
by Erik Landfeldt & Niklas Zethraeus & Peter Lindgren - 25-34 Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance
by Megan Dale & Helen Morgan & Kimberly Carter & Judith White & Grace Carolan-Rees - 35-46 A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges
by Jordana K. Schmier & Jasmine D. Patel & Megan J. Leonhard & Prem A. Midha - 47-54 The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents
by Jonathan J. Darrow & Reed F. Beall & Aaron S. Kesselheim - 55-63 Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations
by Judith J. Gout-Zwart & Erien H. J. Olde Hengel & Petra Hoogland & Maarten J. Postma - 65-76 Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda
by Neily Zakiyah & A. D. I. Asselt & D. Setiawan & Q. Cao & F. Roijmans & M. J. Postma - 77-91 Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States
by Fang Xu & Yong Liu & Anne G. Wheaton & Kristina M. Rabarison & Janet B. Croft - 93-101 Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System
by Irene Eriksson & Mia von Euler & Rickard E. Malmström & Brian Godman & Björn Wettermark - 103-110 Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation
by Stella Nalukwago Settumba & Marian Shanahan & Willings Botha & Muhammad Zulilhaam Ramli & Georgina Mary Chambers - 111-121 The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece
by Georgia Kourlaba & Georgios Hillas & Theodoros Vassilakopoulos & Nikos Maniadakis - 123-124 Comment on: “Does MCDA Trump CEA?”
by Aris Angelis & Panos Kanavos - 125-125 Authors’ Reply to Angelis and Kanavos: “Does MCDA Trump CEA?”
by Carlos Campillo-Artero & Jaume Puig-Junoy & Anthony J. Culyer
December 2018, Volume 16, Issue 6
- 749-751 Potential Impact of Sweetener Input Tax on Public Health
by Prithviraj Lakkakula - 753-763 Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry
by William V. Padula & Jeromie Ballreich & Gerard F. Anderson - 765-778 Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review
by Jamison Pike & Scott D. Grosse - 779-791 SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance
by Tom Macmillan & Mark Pennington & Jennifer A. Summers & Kate Goddard & Darshan Zala & Naomi Herz & Janet L. Peacock & Stephen Keevil & Anastasia Chalkidou - 793-802 Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review
by Etienne Nédellec & Judith Pineau & Patrice Prognon & Nicolas Martelli - 803-817 Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates
by Jaime Espin & Michael Schlander & Brian Godman & Pippa Anderson & Jorge Mestre-Ferrandiz & Isabelle Borget & Adam Hutchings & Steven Flostrand & Adam Parnaby & Claudio Jommi - 819-836 Use of Expert Judgement Across NICE Guidance-Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation
by Alison Peel & Michelle Jenks & Moni Choudhury & Rosemary Lovett & Juan Carlos Rejon-Parrilla & Andrew Sims & Joyce Craig - 837-846 Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran
by Kamran Bagheri Lankarani & Sulmaz Ghahramani & Najmeh Moradi & Hadi Raeisi Shahraki & Farhad Lotfi & Behnam Honarvar - 847-857 Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040
by Scott A. McDonald & Amirah Azzeri & Fatiha Hana Shabaruddin & Maznah Dahlui & Soek S. Tan & Adeeba Kamarulzaman & Rosmawati Mohamed - 859-869 Effects of the ACA on Preventive Care Disparities
by Cagdas Agirdas & Jordan G. Holding - 871-888 Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study
by Atta Abbas Naqvi & Syed Baqir Shyum Naqvi & Fatima Zehra & Ashutosh Kumar Verma & Saman Usmani & Sehrish Badar & Rizwan Ahmad & Niyaz Ahmad - 889-899 Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model
by Katherine M. Prioli & Julie Katz Karp & Nina M. Lyons & Vera Chrebtow & Jay H. Herman & Laura T. Pizzi
October 2018, Volume 16, Issue 5
- 579-581 Gun Policy in the United States: Evidence-Based Strategies to Reduce Gun Violence
by Cassandra Crifasi - 583-590 Opportunities for Use of Blockchain Technology in Medicine
by Igor Radanović & Robert Likić - 591-607 Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage
by Nikolaos Maniadakis & Anke-Peggy Holtorf & José Otávio Corrêa & Fotini Gialama & Kalman Wijaya - 609-632 The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017
by Marcia Reinhart & Lauren M. Scarpati & Noam Y. Kirson & Cody Patton & Nina Shak & Jennifer G. Erensen - 633-651 Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review
by Qinglu Cheng & Nicholas Graves & Rosana E. Pacella - 653-660 The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
by Gerard T. Vondeling & Qi Cao & Maarten J. Postma & Mark H. Rozenbaum - 661-674 The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience
by Thathya V. Ariyaratne & Zanfina Ademi & Molla Huq & Franklin Rosenfeldt & Stephen J. Duffy & Bonny Parkinson & Cheng-Hon Yap & Julian Smith & Baki Billah & Bryan P. Yan & Angela L. Brennan & Lavinia Tran & Christopher M. Reid - 675-684 Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes
by Megha Bansal & Mona Shah & Brian Reilly & Susan Willman & Max Gill & Francine R. Kaufman - 685-695 Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method
by Chun Fan Lee & Raymond Ng & Nan Luo & Yin Bun Cheung - 697-709 Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
by Wallace Breno Barbosa & Juliana de Oliveira Costa & Lívia Lovato Pires Lemos & Rosângela Maria Gomes & Helian Nunes Oliveira & Cristina Mariano Ruas & Francisco de Assis Acurcio & Corrado Barbui & Marion Bennie & Brian Godman & Augusto Afonso Guerra - 711-722 Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy
by Matteo Ruggeri & Federica Romano & Michele Basile & Silvia Coretti & Francesca Romana Rolli & Carlo Drago & Americo Cicchetti - 723-733 Integrating Qualitative Techniques in Model Development: A Case Study Using the Framework Approach
by Samuel N. Frempong & Clare Davenport & Andrew J. Sutton & Justice Nonvignon & Pelham Barton - 735-744 The Choice of Transcatheter Aortic Valve Implementation (TAVI): Do Patient Co-morbidity and Hospital Ownership Type Matter?
by Udo Schneider & Andreas Schmid & Roland Linder & Dirk Horenkamp-Sonntag & Frank Verheyen
August 2018, Volume 16, Issue 4
- 429-432 EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
by Rumona Dickson & Angela Boland & Rui Duarte & Eleanor Kotas & Nerys Woolacott & Robert Hodgson & Rob Riemsma & Sabine Grimm & Bram Ramaekers & Manuela Joore & Nasuh Büyükkaramikli & Eva Kaltenthaler & Matt Stevenson & Abdullah Pandor & Steve Edwards & Martin Hoyle & Jonathan Shepherd & Xavier Armoiry & Miriam Brazzelli - 433-443 The Case for a Private Healthcare Insurance Monopoly
by Paul E. Orzechowski - 445-464 The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance
by Emily Eaton Turner & Michelle Jenks & Rachael McCool & Chris Marshall & Liesl Millar & Hannah Wood & Alison Peel & Joyce Craig & Andrew J Sims - 465-480 Efficiency Measurement in Health Facilities: A Systematic Review in Low- and Middle-Income Countries
by Firdaus Hafidz & Tim Ensor & Sandy Tubeuf - 481-493 Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder
by Tracy Yuen & Melissa T. Carter & Peter Szatmari & Wendy J. Ungar - 495-502 Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia
by Barbara de Graaff & Kwang Chien Yee & Philip Clarke & Andrew Palmer - 503-513 Inference Procedures to Quantify the Efficiency–Equality Trade-Off in Health from Stated Preferences: A Case Study in Portugal
by Micaela Pinho & Anabela Botelho - 515-525 Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
by Gerard Harty & James Jarrett & Mireia Jofre-Bonet - 527-535 Cost-Effectiveness Analysis of Intracapsular Tonsillectomy and Total Tonsillectomy for Pediatric Obstructive Sleep Apnea
by Kenneth Bagwell & Xiao Wu & Eric D. Baum & Ajay Malhotra - 537-548 Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis
by Sarah Wood Pallas & Marissa Courey & Chhaily Hy & Wm. Perry Killam & Dora Warren & Brittany Moore - 549-558 Sugar-Sweetened Beverage Demand and Tax Simulation for Federal Food Assistance Participants: A Case of Two New England States
by Theepakorn Jithitikulchai & Tatiana Andreyeva - 559-567 Public’s Willingness to Pay Towards a Medical Device for Detecting Foot Ulceration in People with Diabetes
by Fan Yang & Brenda Gannon & Andrew Weightman - 569-577 Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
by Fredrik Salvesen Haukaas & Audun Ohna & Tania Krivasi
June 2018, Volume 16, Issue 3
- 275-277 Pricing of HPV Vaccines in Europe: Back to the Future?
by Livio Garattini & Anna Padula - 279-288 Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
by Don Husereau & Brian Feagan & Carl Selya-Hammer - 289-302 Individual and Institutional Corruption in European and US Healthcare: Overview and Link of Various Corruption Typologies
by Margit Sommersguter-Reichmann & Claudia Wild & Adolf Stepan & Gerhard Reichmann & Andrea Fried - 303-315 Economic Studies on Non-Communicable Diseases and Injuries in India: A Systematic Review
by Indrani Gupta & Arjun Roy - 317-330 Long-Term Costs and Health Consequences of Issuing Shorter Duration Prescriptions for Patients with Chronic Health Conditions in the English NHS
by Adam Martin & Rupert Payne & Edward CF Wilson - 331-345 A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
by Lijoy Varghese & Louise Talbot & Andrea Govender & Xu-Hao Zhang & Bruce A. Mungall - 347-355 Spillover Effects of Long-Term Disabilities on Close Family Members
by Diana Pacheco Barzallo - 357-366 Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation
by William J. Valentine & Kate Brunt & Kristina S. Boye & Richard F. Pollock - 367-380 Out of Pocket Costs and Health Insurance Take-Up Rates
by Vasilios D. Kosteas & Francesco Renna - 381-393 Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome
by John M. Brooks & Cole G. Chapman & Mary C. Schroeder - 395-406 Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia
by Ka Keat Lim & Sook Yee Yoon & Nur Aishah Mohd Taib & Fatiha Hana Shabaruddin & Maznah Dahlui & Yin Ling Woo & Meow Keong Thong & Soo Hwang Teo & Nathorn Chaiyakunapruk - 407-414 Does €1 Per Prescription Make a Difference? Impact of a Capped Low-Intensity Pharmaceutical Co-Payment
by Pilar García-Gómez & Toni Mora & Jaume Puig-Junoy - 415-427 Cost-Consequence Analysis Alongside a Randomised Controlled Trial of Hospital Versus Telephone Follow-Up after Treatment for Endometrial Cancer
by Padraig Dixon & Kinta Beaver & Susan Williamson & Chris Sutton & Pierre Martin-Hirsch & William Hollingworth
April 2018, Volume 16, Issue 2
- 147-151 Does MCDA Trump CEA?
by Carlos Campillo-Artero & Jaume Puig-Junoy & Anthony J. Culyer - 153-156 Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia
by David Caldicott & Justin Sinclair & Lynnaire Sheridan & Simon Eckermann - 157-165 Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations
by Ulf Persson & J. M. Norlin - 167-176 A Scoping Review of Economic Evaluations Alongside Randomised Controlled Trials of Home Monitoring in Chronic Disease Management
by Kristian Kidholm & Mie Borch Dahl Kristensen - 177-186 ENDURALIFE-Powered Cardiac Resynchronisation Therapy Defibrillator Devices for Treating Heart Failure: A NICE Medical Technology Guidance
by James Michael Evans & Andrew Cleves & Helen Morgan & Liesl Millar & Grace Carolan-Rees - 187-194 Involving Members of the Public in Health Economics Research: Insights from Selecting Health States for Valuation to Estimate Quality-Adjusted Life-Year (QALY) Weights
by Elizabeth Goodwin & Kate Boddy & Lynn Tatnell & Annie Hawton - 195-205 The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada
by Christiaan H. Righolt & Gurpreet Pabla & Salaheddin M. Mahmud - 207-217 Rich and Well Educated: Are These Requirements Necessary to Claim Healthcare Tax Credits in Italy?
by Elenka Brenna - 219-234 The Determinants of Household Out-of-Pocket (OOP) Medical Expenditure in Rural Bangladesh
by Shamsul Arifeen Khan Mamun & Rasheda Khanam & Mohammad Mafizur Rahman - 235-242 A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia
by Caroline G. Watts & Sally Wortley & Sarah Norris & Scott W. Menzies & Pascale Guitera & Lisa Askie & Graham J. Mann & Rachael L. Morton & Anne E. Cust - 243-257 Cost of Illness for Five Major Foodborne Illnesses and Sequelae in Sweden
by Kristian Sundström - 259-271 Investigating the Willingness to Pay for a Contributory National Health Insurance Scheme in Saudi Arabia: A Cross-sectional Stated Preference Approach
by Mohammed Khaled Al-Hanawi & Kirit Vaidya & Omar Alsharqi & Obinna Onwujekwe - 273-273 Correction to: A Scoping Review of Economic Evaluations Alongside Randomised Controlled Trials of Home Monitoring in Chronic Disease Management
by Kristian Kidholm & Mie Borch Dahl Kristensen
February 2018, Volume 16, Issue 1
- 1-4 Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?
by Livio Garattini & Anna Padula - 5-14 Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions
by Carlos King Ho Wong & Olivia Wu & Bernard M. Y. Cheung - 15-29 A Systematic Review of Cost-of-Illness Studies of Multimorbidity
by Lili Wang & Lei Si & Fiona Cocker & Andrew J. Palmer & Kristy Sanderson - 31-41 Private Health Insurance Incentives in Australia: In Search of Cost-Effective Adjustments
by P. Marcin Sowa & Sam Kault & Joshua Byrnes & Shu-Kay Ng & Tracy Comans & Paul A. Scuffham - 43-54 Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis
by Kathryn Schnippel & Cynthia Firnhaber & Francesca Conradie & Norbert Ndjeka & Edina Sinanovic - 55-64 Healthcare Finance in the Kingdom of Saudi Arabia: A Qualitative Study of Householders’ Attitudes
by Mohammed Khaled Al-Hanawi & Omar Alsharqi & Saja Almazrou & Kirit Vaidya - 65-77 Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis
by Paul Barriere & Géraldine Porcu-Buisson & Samir Hamamah - 79-90 Association Between Medicare’s Mandatory Hospital Value-Based Purchasing Program and Cost Inefficiency
by Germán M. Izón & Chelsea A. Pardini - 91-106 Comparative Cost-Effectiveness Analysis of Three Different Automated Medication Systems Implemented in a Danish Hospital Setting
by Bettina Wulff Risør & Marianne Lisby & Jan Sørensen - 107-122 Scale Effects and Expected Savings from Consolidation Policies of Italian Local Healthcare Authorities
by Cinzia Di Novi & Dino Rizzi & Michele Zanette - 123-132 Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion
by Thibaut Dort & Nadia Schecroun & Baudouin Standaert - 133-143 Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
by Michel L. Peters & Claudine Meijer & Dirk Wyndaele & Walter Noordzij & Annemarie M. Leliveld-Kors & Joan Bosch & Pieter H. Berg & Agni Baka & Jennifer G. Gaultney - 145-145 Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
by Michel L. Peters & Claudine Meijer & Dirk Wyndaele & Walter Noordzij & Annemarie M. Leliveld-Kors & Joan Bosch & Pieter H. Berg & Agni Baka & Jennifer G. Gaultney
December 2017, Volume 15, Issue 6
- 697-706 Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage
by Francesco Paolucci & Ken Redekop & Ayman Fouda & Gianluca Fiorentini - 707-716 Towards Universal Health Coverage via Social Health Insurance in China: Systemic Fragmentation, Reform Imperatives, and Policy Alternatives
by Alex Jingwei He & Shaolong Wu - 717-731 Achieving and Sustaining Universal Health Coverage: Fiscal Reform of the National Health Insurance in Taiwan
by Jesse Yu-Chen Lan - 733-744 Horses for Courses: Moving India towards Universal Health Coverage through Targeted Policy Design
by Dayashankar Maurya & Altaf Virani & S. Rajasulochana - 745-754 Competitive Health Markets and Risk Equalisation in Australia: Lessons Learnt from Other Countries
by Ayman Fouda & Gianluca Fiorentini & Francesco Paolucci - 755-762 How a Bottom-Up Multi-Stakeholder Initiative Helped Transform the Renal Replacement Therapy Landscape in Spain
by Rafael Selgas & Laura Rodriguez & Juan Carlos Julian & Cesar Remon & Mario Prieto-Velasco & Javier Perez-Contreras & Miguel Perez Fontan - 763-772 Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Opportunities and Challenges
by Ramesh Lamsal & Jennifer D. Zwicker - 773-783 Health Expenditure and All-Cause Mortality in the ‘Galaxy’ of Italian Regional Healthcare Systems: A 15-Year Panel Data Analysis
by Davide Golinelli & Fabrizio Toscano & Andrea Bucci & Jacopo Lenzi & Maria Pia Fantini & Nicola Nante & Gabriele Messina - 785-794 A Cost-Benefit Analysis of Two Alternative Models of Maternity Care in Ireland
by Christopher G. Fawsitt & Jane Bourke & Aileen Murphy & Brendan McElroy & Jennifer E. Lutomski & Rosemary Murphy & Richard A. Greene - 795-803 Robustness and Effectiveness of the Triage System in the Pediatric Context
by Marcello Montefiori & Enrico di Bella & Lucia Leporatti & Paolo Petralia - 805-816 Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
by Thomas M. Elliott & David C. Whiteman & Catherine M. Olsen & Louisa G. Gordon - 817-818 Erratum to: Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
by Thomas M. Elliott & David C. Whiteman & Catherine M. Olsen & Louisa G. Gordon
October 2017, Volume 15, Issue 5
- 541-544 Clinical Governance in Italy: ‘Made in England’ for Import?
by Livio Garattini & Anna Padula - 545-555 Out-of-Pocket Payments and Subjective Unmet Need of Healthcare
by Erik Schokkaert & Jonas Steel & Carine Van de Voorde - 557-565 Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries
by Samira Guennif - 567-582 The XprESS Multi-Sinus Dilation System for the Treatment of Chronic Sinusitis: A NICE Medical Technology Guidance
by Michelle Jenks & Iain Willits & Emily Eaton Turner & Neil Hewitt & Mick Arber & Helen Cole & Joyce Craig & Andrew Sims - 583-595 Economic Evaluations of Thrombophilia Screening Prior to Prescribing Combined Oral Contraceptives: A Systematic and Critical Review
by Erin Vernon & Bridget Hiedemann & Bonnie H. Bowie - 597-614 Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data
by Clara Mukuria & Donna Rowen & Mónica Hernández-Alava & Simon Dixon & Roberta Ara - 615-624 User Fees in General Practice: Willingness to Pay and Potential Substitution Patterns—Results from a Danish GP Patient Survey
by Christian Kronborg & Line Bjørnskov Pedersen & Anders Fournaise & Christel Nøhr Kronborg - 625-634 Role of Cost on Failure to Access Prescribed Pharmaceuticals: The Case of Statins
by Ian McRae & Kees Gool & Jane Hall & Laurann Yen - 635-645 A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention
by Jonathan Karnon & Hossein Haji Ali Afzali & Gregorius Virgianto Arpuji Anggoro Putro & Phyu Win Thant & Ameline Dompok & Ingrid Cox & Owen Henry Chikhwaza & Xian Wang & Mercy Mukui Mwangangi & Matahari Farransahat & Ian Cameron - 647-656 Stated Uptake of Physical Activity Rewards Programmes Among Active and Insufficiently Active Full-Time Employees
by Semra Ozdemir & Marcel Bilger & Eric A. Finkelstein - 657-667 Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System
by Dong-Jin Kim & Ho-Sook Kim & Minkyung Oh & Eun-Young Kim & Jae-Gook Shin - 669-679 A Head-to-Head Comparison of UK SF-6D and Thai and UK EQ-5D-5L Value Sets in Thai Patients with Chronic Diseases
by Phantipa Sakthong & Wipaporn Munpan - 681-692 Cost of Trauma Care in Secondary- and Tertiary-Care Public Sector Hospitals in North India
by Ankur Sangwan & Shankar Prinja & Sameer Aggarwal & Jagnoor Jagnoor & Pankaj Bahuguna & Rebecca Ivers
August 2017, Volume 15, Issue 4
- 437-440 We Propose a Novel Measure for Social Welfare and Public Health: Capability-Adjusted Life-Years, CALYs
by Anna Månsdotter & Björn Ekman & Inna Feldman & Lars Hagberg & Anna-Karin Hurtig & Lars Lindholm - 441-445 Clinical, Economic and Policy Implications of Drug Shortages in the European Union
by Elfi De Weerdt & Steven Simoens & Minne Casteels & Isabelle Huys - 447-453 Drug Pricing in South Korea
by Hye-Young Kwon & Brian Godman - 455-468 Spectra Optia® for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology Guidance
by Iain Willits & Helen Cole & Roseanne Jones & Kimberley Carter & Mick Arber & Michelle Jenks & Joyce Craig & Andrew Sims - 469-477 A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
by Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin - 479-490 Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy
by M. Ruggeri & M. Basile & S. Coretti & C. Drago & A. Cicchetti - 491-500 Estimating Willingness to Pay for Online Health Services with Discrete-Choice Experiments
by Jieun Chang & Scott J. Savage & Donald M. Waldman - 501-512 Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
by Ana Teresa Paquete & Luís Silva Miguel & Ursula Becker & Catarina Pereira & Carlos Gouveia Pinto - 513-520 The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act
by Ali Bonakdar Tehrani & Norman V. Carroll - 521-534 Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia
by Barbara Graaff & Amanda Neil & Lei Si & Kwang Chien Yee & Kristy Sanderson & Lyle Gurrin & Andrew J. Palmer - 535-536 Comment on: “Measuring the Volume–Outcome Relation for Complex Hospital Surgery”
by Harold S. Luft - 537-538 Authors’ Reply to Luft: “Measuring the Volume-Outcome Relation for Complex Hospital Surgery”
by Vivian Ho & Woohyeon Kim & Stephen Wolff